Approximately 10–30% of NSCLC neoplasms exhibit activating mutations in the tyrosine kinase structural domain of the EGFR gene, with an increased incidence of up to 60% in Asians patients [4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.